Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 3
Submit an article Journal homepage
486
Views
87
CrossRef citations to date
0
Altmetric
Review

Emerging strategies for the transdermal delivery of peptide and protein drugs

Yannic B SchuetzCentre interuniversitaire de Recherche et d’Enseignement Site d’Archamps, F-74160 ArchampsFrance
,
Aarti NaikSchool of Pharmaceutical Sciences, University of Geneva CH-1211 GenevaSwitzerlandTel: +33 450 315 024; Fax: +33 450 952 832;E-mail: [email protected]
,
Richard H Guy Present address: University of Bath Department of Pharmacy & Pharmacology, Claverton Down, Bath, BA2 7AYUK
&
Yogeshvar N KaliaCentre interuniversitaire de Recherche et d’Enseignement Site d’Archamps, F-74160 ArchampsFrance
Pages 533-548 | Published online: 10 May 2005

Bibliography

  • CEVC G: Drug delivery across the skin. Expert Opin. Investig. Drugs (1997) 6(12):1887–1937.
  • NAIK A. KALIA YN, GUY RH: Transdermal drug delivery: overcoming the skin's barrier function. Pharm. Sci. TechnoL Today (2000) 3(9):318–326.
  • SCHEUPLEIN RJ, BLANK IH: Permeability of the skin. PhysioL Rev. (1971) 51(4):702–747.
  • GUY RH: Current status and future prospects of transdermal drug delivery. Pharm. Res. (1996) 13(12):1765–1769.
  • CHOI H-K, FLYNN GL, AMIDON GL: Transdermal delivery of bioactive peptides: The effect of N-decylmethyl sulfoxide, pH, and inhibitors on enkephalin metabolism and transport. Pharm. Res. (1990) 7(11):1099–1106.
  • BANERJEE PS, RITSCHEL WA: Transdermal permeation of vasopressin. I. Influence of pH, concentration, shaving and surfactant on in vitro permeation. Int. J. Pharm. (1989) 49:189–197.
  • SHAH PK, BORCHARDT RT: A comparison of peptidase activities and peptide metabolism in cultured mouse keratinocytes and neonatal mouse epidermis. Pharm. Res. (1991) 8:70–75.
  • FRAKI JE, LAZARUS GS, HOPSU-HAVU VK: Protein catabolism in the skin. In: Biochemistry and Physiology of the Skin. Goldsmith LA (Ed.), Oxford University Press, New York, USA (1983):338–362.
  • MARTIN RJ, DENYER SP, HADGRAFT J: Skin metabolism of topically applied compounds. Int. j Pharm. (1987) 39:23–32.
  • MORIMOTO K, IWAKURA Y, NAKATANI E et al.: Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontophoretic delivery of calcitonin in rats. J. Pharm. PharmacoL (1992) 44(3):216–218.
  • MORIMOTO K, IWAKURA Y, MIYAZAKI M et al.: Effects of proteolytic enzyme inhibitors of enhancement of transdermal iontophoretic delivery of vasopressin and an analogue in rats. Int. J. Pharm. (1992) 81:119–125.
  • RIESZ P, KONDO T: Free radical formation induced by ultrasound and its biological implications. Free Radical Biol. Med. (1992) 13:247–270.
  • HIKIMA T, HIRAI Y, TOJO K: The effect of ultrasound application on skin metabolism of prednisolone 21-acetate. Pharm. Res. (1998) 15:1680–1683.
  • SMITH EW, MAIBACH HI: Percutaneous Penetration Enhancers. CRC Press, Boca Raton, Florida, USA (1995).
  • WILLIAMS AC, BARRY BW: Penetration enhancers. Adv. Drug Deliv. Rev. (2004) 56:603–618.
  • MARRO D, DELGADO-CHARRO MB, GUY RH: Peptides and proteins - transdermal absorption. In: Encyclopedia of Pharmaceutical Technology. J S JC Boylan (Eds), Marcel Dekker, New York, USA (2002):2125–2140.
  • LASHMAR UT, HADGRAFT J, THOMAS N: Topical application of penetration enhancers to the skin of nude mice: a histopathological study. J. Pharm. PharmacoL (1989) 41(2):118–122.
  • GOZES I, RESHEF A, SALAH D et al.:Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment. Endocrinology (1994) 134:2121–2125.
  • FOLDVARI M, ATTAH-POKU S, HUGHES H et al.: Palmitoyl derivatives of interferon alpha: potential for cutaneous delivery. J. Pharm. Sci. (1998) 87(10):1203–1208.
  • WARANUCH N, RAMACHANDRAN C, WEINER N: Controlled topical delivery of cyclosporin A from nonionic liposomal formulations: mechanistic aspects. J. Liposome Res. (1998) 8(2):225–238.
  • FOLDVARI M, BACA-ESTRADA ME, HE Z et al.: Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon a. Biotechnol. AppL Biochem. (1999) 30:129–137.
  • CEVC G: Transferosomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev.Therap. Drug Carrier Syst. (1996) 13:257–388.
  • CEVC G, GEBAUER D, STIEBER Jet al.:Ultraflexible vesicles, transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta (1998) 1368:201–215.
  • TOUITOU E, GODIN B, WEISS C: Enhanced delivery of drugs into and across the skin by ethosomal carriers. Drug Dev. Res. (2000) 50:406–415.
  • TOUITOU E, DAYAN N, BERGELSON Let al.: Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J. Control. Release (2000) 65:403–418.
  • DAYAN N, TOUITOU E: Carriers for skindelivery of trihexyphenidyl HC1: ethosomes vs liposomes. Biomaterials (2000) 21:1879–1885.
  • JAIN S, UMAMAHESHWARI RB, BHADRA D et al.: Ethosomes: a novel vesicular carrier for enhanced transdermal delivery of an anti-HIV agent. Ind. J. Pharma. Sci. (2004) 66(1):72–81.
  • DKEIDEK I, TOUITOU E: Transdermal absorption of polypeptides. AAPS Pharm. Sci. (1999) 1:S202.
  • BANGA AK, KATAKAM M, MITRA R: Transdermal iontophoretic delivery and degradation of vasopressin across human cadaver skin. Int. j Pharm. (1995) 166:211–216.
  • SARPOTDAR PPDCR, LIVERSIDGE GG, STERNSON LA: Facilitated iontophoretic delivery of thyrotropin releasing hormone (TRH) across cadaver skin by optimization of formulation variables. Pharm. Res. (1989) 6(Suppl.):5107.
  • CLEMESSY M, COUARRAZE G, BEVAN B et al.: Mechanisms involved in iontophoretic transport of angiotensin. Pharm. Res. (1995) 12(7):998–1002.
  • LAU DTW, SHARKEY JW, PETRYK L et al.: Effect of current magnitude and drug concentration on iontophoretic delivery of octreotide acetate (sandostatin) in the rabbit. Pharm. Res. (1994) 11(12):1742–1746.
  • HEIT MC, MONTEIRO-RIVIERE NA, JAYES FL et al.: Transdermal iontophoretic delivery of luteinzing hormone releasing hormone (LHRH): effect of repeated administration. Pharm. Res. (1994) 11 (7): 1000–1003.
  • MILLER LL, KOLASKIE CJ, SMITH GA et al.: Transdermal iontophoresis of gonadotropin releasing hormone (LHRH) and two analogues./ Pharm. Sci. (1990) 79(6):490–493.
  • KNOBLAUCH P, MOLL F: In vitro pulsatile and continuous transdermal
  • RODRIGUEZ BAYON AM, GUY RH: Iontophoresis of nafarelin across human skin in vitro. Pharm. Res. (1996) 13(5):798–800.
  • MEYER BR, KREIS W, ESCHBACHE J et al.: Successfitl transdermal administration of therapeutic doses of a polypeptide to normal human volunteers. Clin. Pharmaco
  • CRAAN-VAN HINSBERG WH BAX L, FLINTERMAN NH et al: Iontophoresis of a model peptide across human skin in vitro: effects of iontophoresis protocol, pH, and 11(9):1296–1300.
  • THYSMAN S, HANCHARD C, PRÉAT V: Human calcitonin delivery in rats by iontophoresis. j Pharm. PharmacoL (1994) 46: 725–730.
  • MEDI BM, SINGH J: Electronically facilitated transdermal delivery of human parathyroid hormone (1-34). Int. J. Pharm. (2003) 263:25–33.
  • SAGE BH: Insulin iontophoresis. In: Protein Delivery - Physical Systems. LM S RW Hendren (Eds), Plenum Publishing Corporation, New York, USA (1997):319–341.
  • GUY RH, KALIA YN, DELGADO-CHARRO MB et al: Iontophoresis: electrorepulsion and electroosmosis. J. Control. Release (2000) 64(1-3):129–132.
  • HIRVONEN J, GUY RH: Iontophoretic delivery across the skin: electroosmosis and its modulation by drug substances. Pharm. Res. (1997) 14(9):1258–1263.
  • DELGADO-CHARRO MB, GUY RH: Characterisation of convective solvent flow during iontophoresis. Pharm. Res. (1994) 11(7):929–935.
  • DELGADO-CHARRO MB, GUY RH: Iontophoretic delivery of nafarelin across the skin. Int. J. Pharm. (1995) 117:165–172.
  • HIRVONEN J, KALIA YN, GUY RH: Transdermal delivery of peptides by iontophoresis. Nat. Biotechnol. (1996) 14(13):1710–1713.
  • HIRVONEN J, GUY RH: Transdermal by polypeptides. J. Control. Release (1998) 50:283–289.
  • ROBERTS MS, KREIS W, ESCHBACHE J et al.: Transdermal versus subcutaneous leuprolide: A comparison of acute pharmacodynamic effect. Clin. Pharmacol. Ther. (1990) 48(4):340–345.
  • HOOGSTRAATE AJ, SRINIVASAN V, SIMS SM et al.: Iontophoretic enhancement of peptides: behaviour of leuprolide versus model permeants. J. Control. Release (1994) 31:41–47.
  • KUMAR S, CHAR H, PATEL S et al: In vivo transdermal iontophoretic delivery of growth hormone releasing factor GRF (1-44) in hairless guinea pigs. J. Control. Release (1992) 18:213–220.
  • LANGKJAER L, BRANGE J, GRODSKY GM et al.: Iontophoresis of monomeric insulin analogues in vitro: effects of insulin charge and skin pretreatment. J. Control. Release (1998) 51:47–56.
  • KALIA YN, NAIK A, GARRISON J et al.: Iontophoretic drug delivery. Adv. Drug Deliv. Rev. (2004) 56(5):619–658.
  • • A comprehensive review of iontophoretic mechanisms and therapeutic applications. Part of a special issue of Advanced Drug Delivery Reviews (2004) 56(5) devoted to transdermal drug delivery technologies (e.g. [53,81]).
  • DENET A-R, VANBEVER R, PRÉAT V: Skin electroporation for transdermal and topical delivery. Adv. Drug Deliv. Rev. (2004) 56:659–674.
  • SEN A, DALY ME, HUI SW: Transdermal insulin delivery using lipid enhanced electroporation. Biochim. Biophys. Acta (2002) 1564:5–8.
  • PRAUSNITZ MR, EDELMAN ER, ELAZER R et al.: Transdermal delivery of heparin by skin electroporation. Biotechnology (1995) 13(11):1205–1209.
  • SERSA G, CEMAZAR M, RUDOLF Z: Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther. (2003) 1:133–142.
  • KOST J: Phonophoresis. In: Electronically Controlled Drug Delivery. B B SM Dinh (Eds), CRC Press, Boca Raton, Florida, USA (1998):215–228.
  • TEZEL A, SENS A, TUSCHERER J et al.: Frequency dependence of sonophoresis. Pharm. Res. (2001) 18:1694–1700.
  • CHIEN YW, SIDDIQUI 0, SHI W-M et al.: Direct current iontophoretic transdermal delivery of peptide and protein drugs. J. Pharm. Sci. (1989) 78(5):376–383.
  • ALVAREZ-ROMAN R, MERINO G, KALIA YN et al.: Skin permeability enhancement by low frequency sonophoresis: lipid extraction and transport pathways. J. Pharm. Sci. (2003) 92(6):1138–1146.
  • MERINO G, KALIA YN, GUY RH: Ultrasound-enhanced transdermal transport. J. Pharm. Sci. (2003) 92(6):1125–1137.
  • BOMMANNAN D, MENON GK, OKUYAMA H et al: Sonophoresis: II. Examination of the mechanism(s) of ultrasound-enhanced transdermal drug delivery. Pharm. Res. (1992) 9:1043–1047.
  • MITRAGOTRI S, EDWARDS D, BLANKSCHTEIN D et al.: A mechanistic study of ultrasonically enhanced transdermal drug delivery. J. Pharm. Sci. (1995) 84(6):697–706.
  • TEZEL A, SENS A, MITRAGOTRI S: Investigations of the role of cavitation in low-frequency sonophoresis using acoustic spectroscopy. J. Pharm. Sci. (2002) 91:444–453.
  • TEZEL A, MITRAGOTRI S: Interactionsof inertial cavitation colapses with stratum corneum lipid bilayers. Biophys. J. (2003) 85:1–11.
  • MITRAGOTRI S, BLANKSCHTEIN D, LANGER R: Ultrasound-mediated transdermal protein delivery. Science (1995) 269:850–853.
  • KRALL LP: World Book of Diabetes in Practice. Elsevier, New York, USA (1988).
  • BOUCAUD A, GARRIGUE MA, MACHET Let al.: Effect of sonication parameters on transdermal delivery of insulin to hairless rats. J. Control. Release (2002) 81:113–119.
  • KATZ NP, SHAPIRO DE, HERRMANN TE et al.: Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound-emitting device. Anesth. Analg. (2004) 98:371–376.
  • SINGER AJ, HOMAN CS, CHURCH AL et al.: Low-frequency sonophoresis: pathologic and thermal effects in dogs. Acad. Emerg. Med. (1998) 5(1):35–40.
  • DOWN JA, HARVEY NG: Minimally invasive systems for transdermal drug delivery. In: Transdermal Drug Delivery. RH G J Hadgraft (Eds), Marcel Dekker, New York, USA (2003):327–359.
  • ••A thorough review of minimally invasive technologies covering the devices, potential applications and limitations.
  • MCALLISTER DV WANG PM, DAVIS SP et al.: Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: Fabrication methods and transport studies. Proc. NatL Acad. Sci. USA (2003) 100(24):13755–13760.
  • MARTANTO W, DAVIS SP, HOLIDAY NR et al.: Transdermal delivery of insulin using microneedles in vivo. Pharm. Res. (2004) 21(61:947–952.
  • CORMIER M, JOHNSON B, AMERI M et al.: Transdermal delivery of desmopressin using a coated microneedle array patch system. J. Control. Release (2004) 97:503–511.
  • CORMIER M, DADDONA P: Macroflux® technology for transdermal delivery of therapeutic proteins and vaccines. In: Modified Release Drug Delivery Systems. MJ R J H MS Roberts MS (Eds), Marcel Dekker, New York, USA (2002):589–598.
  • FJELLESTAD-PAULSEN A, HOGLUND P, LUNDIN S et al.: Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers. Clin. EndocrinoL (1993) 38(2):177–182.
  • MATRIANO JA, CORMIER M, JOHNSON J et al.: Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. (2002) 19(1):63–70.
  • HENRYS, MCALLISTER DV, ALLEN MG et al.: Microfabricated microneedles: a novel approach to transdermal drug delivery. J. Pharm. Sci. (1998) 87(8):922–925.
  • KAUSHIK S, HORD AH, DENSON DD et al.: Lack of pain associated with microfabricated microneedles. Anesth. Analg (2001) 92:502–504.
  • PRAUSNITZ MR: Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. (2004) 56:581–587.
  • SCHRAMM J, MITRAGOTRI S: Transdermal drug delivery by jet injectors: energetics of jet formation and penetration. Pharm. Res. (2002) 19(11):1673–1679.
  • WENIGER BG: Needle-free jet injectionbibliography, device & manufacturer roster and patent list. (2004).
  • KING T: Protein delivery via pre-filled needle-free liquid injection. Drug Delivery Technology (2003) 3(7):52–57.
  • •A concise summary of the state-of-the-art in the technology.
  • BURKOTH TL, BELLHOUSE BJ, HEWSON G et al.: Transdermal and transmucosal powdered drug delivery. Crit. Rev. Therap. Drug Carrier Syst. (1999) 16(4):331–384.
  • DEAN HJ, FULLER D, OSORIO JE: Powder and particle-mediated approaches for delivery of DNA and protein vaccines into the epidermis. Comp. ImmunoL MicrobioL Infect. Dis. (2003) 26:373–388.
  • SCHNEIDER U, BIRNBACHER R, SCHOBER E: Painfulness of needle and jet injection in children with diabetes mellitus. Eur. J. Pediatr. (1994) 153(6):409–410.
  • DORR HG, ZABRANSKY S, KELLER E et al.: Are needle-free injections a useful alternative for growth hormone therapy in children? Safety and pharmacokinetics of growth hormone delivered by a new needle-free injection device compared to a fine gauge needle. J. Pediatr. EndocrinoL Metab. (2003) 16(3):383–392.
  • AGERSO H, MOLLER-PEDERSEN J, CAPPI S et al.: Pharmacokinetics and pharmacodynamics of a new formulation of recombinant human growth hormone administered by ZomaJet 2 Vision, a new needle-free device, compared to subcutaneous administration using a conventional syringe. J. Clin. Pharma. (2002) 42:1262–1268.
  • VERRIPS GH, HIRASING RA, FEKKES M et al.: Psychological responses to the needle-free Medi-Jector or the multidose Disetronic injection pen in human growth hormone therapy. Acta Paediatrica (1998) 87(2):154–158.
  • BENNETT J, NICHOLS F, ROSENBLUM M et al.: Subcutaneous administration of midazolam: a comparison of the Bioject jet injector with the conventional syringe and needle. J. Oral Maxillofac. Surg (1998) 56(11):1249–1254.
  • MURRAY FT: HIV patient acceptance of a needle-free device (SeroJetTm) for administering recombinant human growth hormone in the treatment of HIV infection-associated cachexia. Today's Therapeutic Trends (2001) 19(4):283–295.
  • MURRAY FT, WRIGHT GJ, LANDY H et al.: Comparative bioequivalence and patient acceptance of recombinant human growth hormone administered by a needle- free jet injector device or standard syringe injection. Today's Therapeutic Trends (2001) 19:137–155.
  • SVEDMAN P, LUNDI S, SVEDMAN C: Administration of antidiuretic peptide (DDAVP) by way of suction de-epithelialised skin. Lancet (1991) 337: 1506–1509.
  • LUNDIN S, SVEDMAN P, HOGLUND P et al.: Absorption of an oxytocin antagonist (Antocin) and a vasopressin analogue (dDAVP) through a standardized skin erosion in volunteers. Pharm. Res. (1995) 12(12):2024–2029.
  • WESTERLING D, HOGLUND P, LUNDIN S et al.: Transdermal administration of morphine to healthy subjects. Br. J. Clin. PharmacoL (1994) 37(6):571–576.
  • SVEDMAN P, LUNDI S, HOGLUND P et al.: Passive drug diffusion via standardized skin mini-erosion; methodological aspects and clinical findings with new device. Pharm. Res. (1996) 13(9):1354–1359.
  • MANALOTO RMP, ALSTER T: Erbium:YAG laser resurfacing for refractory melasma. DermatoL Surg (1999) 25(2):121–123.
  • LEE W-R, SHEN S-C, WANG K-H et al:The effect of laser treatment on skin to enhance and control transdermal deliver of 5-fluorouracil. j Pharm. Sci. (2002) 91(7):1613–1626.
  • NELSON JS, MCCULLOUGH JL, GLENN TC et al.: Mid-infrared laser ablation of stratum corneum enhances in vitro percutaneous transport of drugs. J. Invest. DermatoL (1991) 97(5):874–879.
  • SINTOV AC, KRYMBERK I, DANIEL D et al.: Radiofrequency-driven skin microchanneling as a new way for electrically assisted transdermal delivery of hydrophilic drugs./ Control. Release (2003) 89:311–320.
  • LEVIN G, GERSHONOWITZ A, SHERMAN A et al.: ViadermTm - novel microelectronic device enhances skin permeability of human growth hormone. (2003).
  • MITRAGOTRI S: Synergistic effect of enhancers for transdermal drug delivery. Pharm. Res. (2000) 17(11):1354–1359.
  • CHOI EH, LEE SH, AHN SK et al.: The pretreatment effect of chemical skin penetration enhancers in transdermal drug delivery using iontophoresis. Skin PharmacoL AppL Skin PhysioL (1999) 12:326–335.
  • PILLAI O, NAIR V, PANCHAGNULA R: Transdermal iontophoresis of insulin: IV. Influence of chemical enhancers. Int. J. Pharm. (2004) 269(1):109–120.
  • BOMMANNAN DB: Effect of electroporation on transdermal iontophoretic delivery of luteinizing hormone releasing hormone (LHRH) in vitro. Pharm. Res. (1994) 11(12):1809–1814.
  • SUGIBAYASHI K, KAGINO M, NUMAJIRI S et al.: Synergistic effects of iontophoresis and jet injector pretreatment on the in-vitro skin permeation of diclofenac and angiotensin. J. Pharm. Pharmacol. (2000) 52:1179–1186.
  • MEEHAN E, GROSS Y, DAVIDSON D et al.: A microinfusor device for the delivery of therapeutic levels of peptides and macromolecules. J. Control. Release (1996) 46:107–116.
  • DOUKAS AG, FLOTTE TJ: Physical characteristics and biological effects of laser-induced stress waves. Ultrasound Med. Biol. (1996) 22:151–164.
  • DOUKAS AG, MCAULIFFE DJ, LEE S et al.: Physical factors involved in stress-wave-induced cell injury: The effect of stress gradient. Ultrasound Med. Biol. (1995) 21:961–967.
  • LEES, KOLLIAS N, MCAULIFFE DJ et al.: Topical drug delivery in humans with a single photomechanical wave. Pharm. Res. (1999) 16(11):1717–1721.
  • LEE S, MCAULIFFE DJ, FLOTTE TJ et al.: Photomechanical transcutaneous delivery of macromolecules. J. Invest. DermatoL (1998) 111:925–929.
  • LEE S, MCAULIFFE DJ, FLOTTE TJ et al.: Photomechanical transdermal delivery: the effect of laser confinement. Lasers Surg Med. (2001) 28(4):344–347.
  • LEE S, MCAULIFFE DJ, KOLLIAS N et al.: Photomechanical delivery of 100-nm microspheres through the stratum corneum: implications for transdermal drug delivery. Lasers Surg Med. (2002) 31(3):207–210.
  • LEE S, MCAULIFFE DJ, MULHOLLAND SE et al.: Photomechanical transdermal delivery of insulin in vivo. Lasers Surg. Med. (2001) 28(3):282–285.
  • SHOMAKER TS, ZHANG J, LOVE G et al.: Evaluating skin anesthesia after administration of local anesthetic system consisting of an S-Caine patch and a controlled heat-aided drug delivery (CHADD) patch in volunteers. Clin. Pain (2000) 16(3):200–204.
  • HERNDON TO, GONZALEZ S, GOWRISHANKAR TR et al.: Transdermal microconduits by microscission for drug delivery and sample acquisition. BMC Medicine (2004) 2(1):12.
  • OBERYÉ J, MANNAERTS B, HUISMAN J et al.: Local tolerance, pharmacokinetics, and dynamics of ganirelix (orgalutran) administration by Medi-Jector compared to conventional needle injections. Hum. Reprod. (2000) 15(2):245–249.
  • Cool.click: a needle-free device for growth hormone delivery. Med. Lett. Drugs Therap. (2001) 43:2–3.
  • HOUDIJK E, HERDES E, DELEMARRE-VAN WAAL H: Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle-injection in patients with growth hormone deficiency. Acta Paediatrica (1997) 86:1301–1307.

Website

  • http://www.cdc.govinip/dev/Jetinject-Bib.pdf Needle-free injection technology: bibliographic references, device & manufacturer roster and patents list.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.